Showing 3671-3680 of 7279 results for "".
- Tomatoes May Slash Skin Cancer Riskhttps://practicaldermatology.com/news/tomatoes-may-slash-skin-cancer-risk/2458122/Daily tomato consumption may cut skin cancer risk in half, according to a new study in mice. The Ohio State University researchers report their findings online in the journal
- FDA Clears Philips BlueControl Wearable Light Therapy Device to Treat Mild Psoriasis At Homehttps://practicaldermatology.com/news/fda-clears-philips-bluecontrol-wearable-light-therapy-device-to-treat-mild-psoriasis-at-home/2458124/The FDA has granted Royal Philips 510(k) clearance to market the Philips BlueControl wearable light therapy device to treat mild psoriasis. In the US, BlueControl is a Class II prescription medical device designed for home use. Clinical studies have demonstrated that the UV-free blue LED
- FDA Approves Janssen's Tremfya for Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-janssens-tremfya-for-moderate-to-severe-plaque-psoriasis/2458123/The FDA has approved Janssen's Tremfya (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine that plays a
- Allergan CEO: Consensus Needed on Medical Aesthetic Treatment in Minorshttps://practicaldermatology.com/news/allergan-ceo-consensus-needed-on-medical-aesthetic-treatment-in-minors/2458125/Allergan Chairman & CEO Brent Saunders, the father of two high school-aged girls, is speaking up and out about the risks associated with offering medical aesthetic treatments to minors. In a new blog post, he writes “we must remember that anyone under the age of 18 is still matu
- High Doses of Sunshine Vitamin May Improve Sunburnhttps://practicaldermatology.com/news/high-doses-of-sunshine-vitamin-may-improve-sunburn/2458128/High doses of vitamin D taken one hour after sunburn may significantly reduce skin redness, swelling, and inflammation, according to double-blinded, placebo-controlled clinical trial out of Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center.
- Samsung Biologics to Manufacture Sun Pharma's Tildrakizumab for Psoriasishttps://practicaldermatology.com/news/samsung-biologics-to-manufacture-sun-pharmas-tildrakizumab-for-psoriasis/2458130/Sun Pharmaceutical Industries just inked a long-term agreement with South Korea’s Samsung BioLogics to manufacture Tildrakizumab for psoriasis. The investigational IL-23p19 inhibitor drug is currently under review by the US Food & Drug Admi
- Array BioPharma Submits NDAs for Binimetinib and Encorafenib in Advanced Melanomahttps://practicaldermatology.com/news/array-biopharma-submits-ndas-for-binimetinib-and-encorafenib-in-advanced-melanoma/2458131/Array BioPharma submitted two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for the use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with&nbs
- Braun Survey: Many Men Fret About Sensitive Skinhttps://practicaldermatology.com/news/braun-survey-many-men-fret-over-sensitive-skin/2458133/Dry, sensitive or red skin is a major key cause for anxiety among UK men, and this often impedes upon their quality of life, according to a new survey from Braun. More than one in three (34 percent) of the 7,074 men surveyed described their sk
- FDA Approves SciBase's Nevisense for Melanoma Detectionhttps://practicaldermatology.com/news/fda-approved-scibases-nevisense-for-melanoma-diagnosis/2458136/The FDA has approved the Scibase Pre-Market Approval (PMA) for Nevisense, a device for the early detection of malignant melanoma. According to the letter from the FDA the device is intended for use on cutaneous lesions with one or more clinical or historical characteristics of melano
- CARD11 Mutations May Lead to ADhttps://practicaldermatology.com/news/card11-mutations-may-lead-to-ad/2458150/Researchers have identified mutations in a gene called CARD11 that may lead to atopic dermatitis. Their findings, reported in Nature Genetics</